Free Writing Prospectus
Filed Pursuant to Rule 433
Registration Statement No. 333-209627
Dated May 4, 2017
Filed Pursuant to Rule 433
Registration Statement No. 333-209627
Dated May 4, 2017
Eli Lilly and Company
Pricing Term Sheet
2.350% Notes due 2022
3.100% Notes due 2027
3.950% Notes due 2047
Issuer: | Eli Lilly and Company | ||
2.350% Notes due 2022 | 3.100% Notes due 2027 | 3.950% Notes due 2047 | |
Principal Amount: | $750,000,000 | $750,000,000 | $750,000,000 |
Maturity Date: | May 15, 2022 | May 15, 2027 | May 15, 2047 |
Coupon: | 2.350% per year | 3.100% per year | 3.950% per year |
Public Offering Price: | 99.849% of principal amount | 99.965% of principal amount | 99.459% of principal amount |
Yield to Maturity: | 2.382% | 3.104% | 3.981% |
Benchmark Treasury: | 1.875% due April 30, 2022 | 2.250% due February 15, 2027 | 2.875% due November 15, 2046 |
Spread to Benchmark Treasury: | T+50 bps | T+75 bps | T+98 bps |
Benchmark Treasury Price / Yield: | 99-31 / 1.882% | 99-03 / 2.354% | 97-17+ / 3.001% |
Interest Payment Dates: | May 15 and November 15, commencing November 15, 2017 | May 15 and November 15, commencing November 15, 2017 | May 15 and November 15, commencing November 15, 2017 |
Redemption Provisions: | |||
Make-whole call: | Make whole plus 7.5 bps | Prior to February 15, 2027, make whole plus 12.5 bps (calculated to the par call date) | Prior to November 15, 2046, make whole plus 15 bps (calculated to the par call date) |
Par call: | On or after February 15, 2027, at 100% | On or after November 15, 2046, at 100% | |
CUSIP / ISIN: | 532457 BQ0 / US532457BQ09 | 532457 BP2 / US532457BP26 | 532457 BR8 / US532457BR81 |
Trade Date: | May 4, 2017 | ||
Settlement Date: | May 9, 2017 (T+3) | ||
Denominations: | $2,000 x $1,000 | ||
Joint Book-Running Managers: | J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated, Morgan Stanley & Co. LLC and Barclays Capital Inc. |
Co-Managers: | BNP Paribas Securities Corp., Drexel Hamilton, LLC and MUFG Securities Americas Inc. |
The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling J.P. Morgan Securities LLC collect at (212) 834-4533, Merrill Lynch, Pierce, Fenner & Smith Incorporated toll-free at (800) 294-1322 and Morgan Stanley & Co. LLC toll-free at (866) 718-1649.
2